Last 7 days
0.3%
Last 30 days
1.3%
Last 90 days
-4.6%
Trailing 12 Months
383.3%
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Revenue | -96.6% | 458,000 | 13,638,667 | 26,819,333 | 40,000,000 | 26,692,000 |
Gross Profit | -99.7% | 112,000 | 40,000,000 | 160,000,000 | - | - |
Operating Expenses | -29.4% | 75,862,000 | 107,482,000 | 115,522,000 | - | - |
S&GA Expenses | -10.2% | 26,579,000 | 29,606,000 | 32,065,000 | - | - |
R&D Expenses | -36.7% | 49,283,000 | 77,876,000 | 83,457,000 | - | - |
EBITDA | -25.1% | -67,291,000 | -53,778,000 | -58,153,000 | - | - |
EBITDA Margin | -10828.2% | -146 | -1.34 | -1.45 | - | - |
Earnings Before Taxes | -25.0% | -68,448,000 | -54,776,000 | -59,132,000 | - | - |
EBT Margin | -10813.5% | -149 | -1.37 | -1.48 | - | - |
Interest Expenses | 50.6% | 521,000 | 346,000 | 340,000 | - | - |
Net Income | -25.3% | -68,701,000 | -54,814,000 | -59,116,000 | - | - |
Net Income Margin | -10846.3% | -150 | -1.37 | -1.48 | - | - |
Free Cahsflow | -109.8% | -59,891,000 | -28,551,000 | -29,227,000 | - | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | 24.5% | 323 | 259 | 275 | 155 | 169 |
Current Assets | 26.3% | 307 | 243 | 258 | 139 | 153 |
Cash Equivalents | 27.9% | 291 | 228 | 232 | 112 | 133 |
Net PPE | -83.6% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Goodwill | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | 60.0% | 46.00 | 29.00 | 37.00 | 44.00 | 43.00 |
Current Liabilities | 39.4% | 27.00 | 19.00 | 32.00 | 39.00 | 38.00 |
LT Debt, Non Current | 102.8% | 20.00 | 10.00 | 5.00 | 5.00 | 5.00 |
Shareholder's Equity | 20.1% | 277 | 230 | 237 | 111 | 126 |
Retained Earnings | -5.1% | -350 | -333 | -322 | -306 | -288 |
Additional Paid-In Capital | 11.7% | 591 | 529 | 526 | 391 | 388 |
Shares Outstanding | 4.2% | 632 | 606 | 602 | 485 | 483 |
Cashflow (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | 14.6% | -51,132 | -59,862 | -69,447 | -28,527 | -29,215 |
Share Based Compensation | 3.8% | 14,663 | 14,121 | 13,804 | 15,926 | 20,323 |
Cashflow From Investing | 0% | -29.00 | -29.00 | -30.00 | -41.00 | -12.00 |
Cashflow From Financing | 49.3% | 210,229 | 140,818 | 137,303 | -4,133 | -6,843 |
100%
100%
87.7%
Y-axis is the maximum loss one would have experienced if Verona Pharma was unfortunately bought at previous high price.
5.2%
64.4%
FIve years rolling returns for Verona Pharma.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | new | - | 143,000 | 143,000 | -% |
2023-05-18 | JPMORGAN CHASE & CO | added | 11,167 | 4,319,000 | 4,369,000 | -% |
2023-05-16 | PERCEPTIVE ADVISORS LLC | reduced | -43.99 | -72,638,700 | 54,894,500 | 1.62% |
2023-05-15 | Samsara BioCapital, LLC | unchanged | - | -4,204,760 | 13,955,600 | 2.87% |
2023-05-15 | CITADEL ADVISORS LLC | new | - | 5,386,420 | 5,386,420 | -% |
2023-05-15 | ORBIMED ADVISORS LLC | reduced | -6.81 | -33,919,200 | 85,554,700 | 1.68% |
2023-05-15 | Affinity Asset Advisors, LLC | added | 44.9 | 927,073 | 9,092,650 | 3.00% |
2023-05-15 | Artia Global Partners LP | added | 126 | 772,336 | 1,816,260 | 0.67% |
2023-05-15 | Caligan Partners LP | unchanged | - | -1,107,540 | 3,675,920 | 2.56% |
2023-05-15 | Shay Capital LLC | new | - | 271,080 | 271,080 | 0.05% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
May 16, 2023 | orbimed advisors llc | 4.8% | 3,777,778 | SC 13D/A | |
Apr 25, 2023 | access industries holdings llc | 0% | 0 | SC 13G/A | |
Apr 20, 2023 | perceptive advisors llc | 5.6% | 4,462,666 | SC 13G | |
Feb 14, 2023 | vivo ventures vii, llc | 3.8% | 23,142,200 | SC 13G/A | |
Feb 14, 2023 | ra capital management, l.p. | 9.99% | 7,691,990 | SC 13G/A | |
Feb 09, 2023 | access industries holdings llc | 5.45% | 32,946,296 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 4.43% | 26,770,960 | SC 13G/A | |
Dec 27, 2022 | orbimed advisors llc | 5.6% | 4,260,691 | SC 13D/A | |
Sep 07, 2022 | growth equity opportunities fund iv, llc | 7.9% | 46,447,651 | SC 13D/A | |
Feb 14, 2022 | ra capital management, l.p. | 9.99% | 48,778,172 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
May 16, 2023 | SC 13D/A | 13D - Major Acquisition | |
May 15, 2023 | 4 | Insider Trading | |
May 15, 2023 | 4 | Insider Trading | |
May 11, 2023 | 144 | Notice of Insider Sale Intent | |
May 11, 2023 | 4/A | Insider Trading | |
May 11, 2023 | 4/A | Insider Trading | |
May 09, 2023 | 8-K | Current Report | |
May 09, 2023 | S-8 | Employee Benefits Plan | |
May 09, 2023 | 10-Q | Quarterly Report | |
May 03, 2023 | 144 | Notice of Insider Sale Intent |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-15 | Gupta Rishi | sold | -7,222,480 | 20.0785 | -359,713 | - |
2023-05-15 | ORBIMED ADVISORS LLC | sold | -7,222,480 | 20.0785 | -359,713 | - |
2023-05-12 | ORBIMED ADVISORS LLC | sold | -934,848 | 21.64 | -43,200 | - |
2023-05-12 | Gupta Rishi | sold | -934,848 | 21.64 | -43,200 | - |
2023-05-11 | Gupta Rishi | sold | -1,780,800 | 22.26 | -80,000 | - |
2023-05-11 | ORBIMED ADVISORS LLC | sold | -1,780,800 | 22.26 | -80,000 | - |
2023-05-03 | Rickard Kathleen A. | sold | -76,241 | 2.6517 | -28,752 | chief medical officer |
2023-05-01 | Poll Claire | acquired | - | - | 8,328 | general counsel |
2023-05-01 | ZACCARDELLI DAVID | sold | -1,173,420 | 2.5759 | -455,536 | president and ceo |
2023-05-01 | Rickard Kathleen A. | acquired | - | - | 15,000 | chief medical officer |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 12,610 | $ 17,625 |
Selling, general and administrative | 9,589 | 7,440 |
Total operating expenses | 22,199 | 25,065 |
Operating loss | (22,199) | (25,065) |
Other income/(expense): | ||
Research and development tax credit | 2,313 | 1,302 |
Interest income | 2,677 | 15 |
Interest expense | (293) | (84) |
Foreign exchange gain/(loss) | 932 | (923) |
Total other income, net | 5,629 | 310 |
Loss before income taxes | (16,570) | (24,755) |
Income tax expense | (173) | (82) |
Net loss | $ (16,743) | $ (24,837) |
Profit/(loss) per share, basic (in dollars per share) | $ (0.03) | $ (0.05) |
Profit/(loss) per share, diluted (in dollars per share) | $ (0.03) | $ (0.05) |
Weighted-average shares outstanding, basic (in shares) | 621,451,000 | 481,942,000 |
Weighted-average shares outstanding, diluted (in shares) | 621,451,000 | 481,942,000 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 291,415 | $ 227,827 |
Prepaid expenses | 1,561 | 2,499 |
Tax incentive receivable | 11,842 | 9,282 |
Other current assets | 2,073 | 3,388 |
Total current assets | 306,891 | 242,996 |
Non-current assets: | ||
Furniture and equipment, net | 12 | 73 |
Goodwill | 545 | 545 |
Equity interest | 15,000 | 15,000 |
Right-of-use assets | 698 | 854 |
Total non-current assets | 16,255 | 16,472 |
Total assets | 323,146 | 259,468 |
Current liabilities: | ||
Accounts payable | 7,237 | 2,910 |
Accrued expenses | 17,703 | 13,752 |
Current operating lease liabilities | 650 | 675 |
Taxes payable | 424 | 283 |
Other current liabilities | 509 | 1,409 |
Total current liabilities | 26,523 | 19,029 |
Non-current liabilities: | ||
Term loan | 19,809 | 9,768 |
Non-current operating lease liabilities | 65 | 205 |
Total non-current liabilities | 19,874 | 9,973 |
Total liabilities | 46,397 | 29,002 |
Commitments and contingencies | ||
Shareholders' equity: | ||
Ordinary £0.05 par value shares; 651,659,630 and 631,338,246 issued, and 631,987,078 and 606,301,054 outstanding, at March 31, 2023 and December 31, 2022, respectively | 41,753 | 40,526 |
Additional paid-in capital | 590,915 | 529,187 |
Ordinary shares held in treasury | (1,208) | (1,549) |
Accumulated other comprehensive loss | (4,601) | (4,601) |
Accumulated deficit | (350,110) | (333,097) |
Total shareholders' equity | 276,749 | 230,466 |
Total liabilities and shareholders' equity | $ 323,146 | $ 259,468 |